711 unknown. 711 Phase 2, 115 Phase 1, 28 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 711 | Unknown 711 |
| Phase 1 | 115 | Unknown 115 |
| Phase 3 | 28 | Unknown 28 |
Follow Respiratory Tract Neoplasms: new trials by email Literature Review of Respiratory Tract Neoplasms trials Research Report on Respiratory Tract Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cerebrospinal Fluid Immune Microenvironment Mechanism in Anaplastic Lymphoma Kinase Positive Lung Cancer Patients Iruplinalib - Carcinoma, Non-Small-Cell Lung | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 12 | 2024-12-01 | 2024-11-20 |
| Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic Intrathecal Pemetrexed - Small-cell Lung Cancer | Phase 2 | Unknown | Hunan Province Tumor Hospital | 80 | 2024-10-01 | 2024-09-19 |
| Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases Intrathecal Pemetrexed and high-dose Furmonertinib plus bevacizumab - Non-small Cell Lung Cancer | Phase 2 | Unknown | Hunan Province Tumor Hospital | 30 | 2024-09-30 | 2024-09-20 |
| A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer SHR-A2102, Adebelimab (SHR-1316), SHR-8068 - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | Shanghai Hengrui Pharmaceutical Co., Ltd. | 124 | 2024-09-27 | 2024-11-12 |
| PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) PH009-1 tablet - Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Unknown | Suzhou Puhe Pharmaceutical Technology Co., LTD | 96 | 2024-09-10 | 2024-09-19 |
| Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations Neratinib tablets - Advanced Solid Tumor | Phase 2 | Unknown | Convalife (Shanghai) Co., Ltd. | 60 | 2024-08-10 | 2024-07-25 |
| FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy - Non-small Cell Lung Cancer | Phase 2 | Unknown | Changzhou No.2 People's Hospital | 62 | 2024-06-01 | 2024-12-20 |
| Radiotherapy to All Residual Lesions After Chemoimmunotherapy Radiotherapy to all residual lesions, Chemoimmunotherapy - Extensive-stage Small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | Anhui Provincial Hospital | 150 | 2024-06-01 | 2024-08-09 |
| Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer Almonertinib - Lung Cancer Non-small Cell Stage IV | Phase 2 | Unknown | Shanghai Pulmonary Hospital, Shanghai, China | 60 | 2024-06-01 | 2024-06-17 |
| Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection Durvalumab, Non-ablative oligofractionated radiation (NORT) - Lung Cancer Patients, Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Unknown | Marc de Perrot | 12 | 2024-05-22 | 2024-07-22 |
| High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib Furmonertinib - Non-Small Cell Lung Cancer | Phase 2 | Unknown | Changhai Hospital | 84 | 2024-05-01 | 2024-07-26 |
| Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy SBRT or LDRT, PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy - NSCLC Stage IV | Phase 2 | Unknown | Fudan University | 146 | 2024-04-10 | 2024-06-05 |
| Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer anlotinib combined with penpulimab - Non-small Cell Lung Cancer | Phase 2 | Unknown | The First Affiliated Hospital of Zhengzhou University | 33 | 2024-01-31 | 2024-04-02 |
| Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) Camrelizumab, Thalidomide 50mg, Thalidomide 100mg - Lung Cancer, Nonsmall Cell, Esophageal Carcinoma | Phase 2 | Unknown | Henan Cancer Hospital | 132 | 2024-01-19 | 2024-03-29 |
| Trial of Tumor Vaccine Used for Adjuvant Therapy in Post Radical Operation Patients With Lung Cancer Tumor Vaccine - Lung Cancer | Phase 1 / Phase 2 | Unknown | Yongchang Zhang | 30 | 2024-01-16 | 2023-12-29 |
| Development of a Fluorescent Visualization System for Non-visible Lung Cancer Nodules Cetuximab-IRDye800 - Lung Cancer, Video-assisted Thoracic Surgery | Phase 2 | Unknown | University of Turin, Italy | 25 | 2024-01-01 | 2024-01-25 |
| A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors Efgbemalenograstim alfa - Non Small Cell Lung Cancer | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 99 | 2023-12-31 | 2023-11-22 |
| Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy Adebrelimab Combined with Bevacizumab and Docetaxel - Non-small Cell Lung Cancer | Phase 2 | Unknown | The First Affiliated Hospital of Xinxiang Medical College | 35 | 2023-12-27 | 2023-12-27 |
| Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC IBI-323 combined with bevacizumab plus Platinum - Non Small Cell Lung Cancer | Phase 2 | Unknown | Hunan Province Tumor Hospital | 70 | 2023-12-25 | 2024-01-10 |
| A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC Adebrelimab, Carboplatin/Cisplatin, Etoposide - Respiratory Tract Neoplasms, Thoracic Neoplasms | Phase 2 | Unknown | Nanfang Hospital, Southern Medical University | 62 | 2023-12-10 | 2023-12-20 |
Showing 20 of 711. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (490) · Lung Neoplasms (164) · Small Cell Lung Carcinoma (92) · Brain Neoplasms (26) · Adenocarcinoma of Lung (22) · Mesothelioma, Malignant (19) · Breast Neoplasms (18) · Melanoma (16) · Neoplasms (15) · Stomach Neoplasms (15) · Pancreatic Neoplasms (14) · Carcinoma, Renal Cell (12) · Colorectal Neoplasms (12) · Pleural Effusion, Malignant (12) · Head and Neck Neoplasms (10)
Neoplasms by Site (710) · Thoracic Neoplasms (699) · Neoplasms (696) · Respiratory Tract Diseases (695) · Lung Diseases (675) · Carcinoma, Bronchogenic (574) · Bronchial Neoplasms (573) · Lung Neoplasms (528) · Neoplasms by Histologic Type (87) · Neoplasms, Glandular and Epithelial (81) · Carcinoma (54) · Adenocarcinoma (40) · Digestive System Diseases (34) · Skin and Connective Tissue Diseases (34)
Carboplatin (72) · Cisplatin (72) · Docetaxel (56) · Pemetrexed (54) · Erlotinib Hydrochloride (34) · Gemcitabine (34) · anlotinib (30) · Bevacizumab (28) · Drug Therapy (28) · apatinib (28) · Etoposide (26) · Gefitinib (24) · Radiotherapy (24) · icotinib (24) · camrelizumab (23)
Sun Yat-sen University (25) · Tianjin Medical University Cancer Institute and Hospital (17) · Fudan University (15) · Zhejiang Cancer Hospital (15) · Betta Pharmaceuticals Co., Ltd. (14) · National Cancer Center, Korea (13) · Hunan Province Tumor Hospital (12) · Samsung Medical Center (12) · Shanghai Chest Hospital (12) · The First Affiliated Hospital of Guangzhou Medical University (11) · Henan Cancer Hospital (10) · Sichuan Cancer Hospital and Research Institute (10) · Yonsei University (9) · Chinese Academy of Medical Sciences (8) · Guangdong Association of Clinical Trials (8)
China (383) · United States (60) · South Korea (54) · Italy (23) · France (13) · United Kingdom (13) · Belgium (12) · Germany (12) · Taiwan (12) · Spain (11) · Canada (8) · Israel (8) · Japan (7) · Australia (6) · Netherlands (6)
Jianxing He, MD, FACS (4) · Liu Anwen, Phd (4) · Caicun Zhou, MD,PhD (3) · Francisco Aparisi, Doctor (3) · Gaspar Esquerdo, Doctor (3) · Heung Tae Kim, M.D. (3) · Jian Fang (3) · Joo-Hang Kim, MD (3) · Juan Li, MD (3) · Li Zhang (3) · Mengzhao Wang, MD (3) · Oscar Juan, Doctor (3) · Shenglin Ma, MD (3)
PMID 16204011, PMID 17075123, PMID 19692680, PMID 25497558, PMID 26104945, PMID 30207593, PMID 30596880, PMID 31085043, PMID 31751012, PMID 32346071, PMID 32916310, PMID 40354010, PMID 10704469, PMID 10811675, PMID 10856094, PMID 10999768, PMID 11452123, PMID 11698646, PMID 11784875, PMID 11786587, PMID 11910893, PMID 12091876, PMID 12218188, PMID 12457271, PMID 12467231, PMID 12538684, PMID 12695859, PMID 12748244, PMID 12750523, PMID 14570950, PMID 14679114, PMID 14756433, PMID 14967075, PMID 15117980, PMID 15457249, PMID 15598424, PMID 15771580, PMID 15778874, PMID 15800326, PMID 15857739, PMID 15886314, PMID 16012180, PMID 16014882, PMID 16107633, PMID 16111068, PMID 16170339, PMID 16257339, PMID 16271509, PMID 16376734, PMID 16408219
2015 (3), 2008 (2), 2016 (2), 2018 (2), 2019 (2), 2005 (1), 2017 (1), P30CA060553 (1)